Condition: Extrahepatic Cholangiocarcinoma · Unresectable Perihilar or Ductal CCA · Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial. Patients with unresectable perihilar and/or ductal CCA with indication for bile duct stenting and palliative systemic therapy as determined by the local multidisciplinary team (MDT), who already resolved cholestasis due to RFA + Stent will be enrolled. We hypothesize that in patients with extrahepatic cholangiocarcinoma, the use of a combination radiofrequency ablation followed by systemic treatment with chemotherapy plus durvalumab might further increase the anti-tumor activity.
This description comes directly from the study's public registry record.
Christoph Roderburg, Prof. Dr. · +49 211 8108030 · christoph.roderburg@med.uni-duesseldorf.de
Johanna Riedel, Dr. · +49 69 5899 787 · clean-duct@ikf-khnw.de
Always discuss trial participation with your own doctor first.
| Uniklinik RWTH Aachen | Aachen, Germany | Recruiting |
| Universitätsklinikum Bonn | Bonn, Germany | Recruiting |
| Universitätsklinikum Köln | Cologne, Germany | Recruiting |
| Universitätsklinikum Düsseldorf | Düsseldorf, Germany | Recruiting |
| Krankenhaus Nordwest | Frankfurt, Germany | Recruiting |
| Universitätsmedizin Göttingen | Göttingen, Germany | Recruiting |
| Medizinische Hochschule Hannover | Hanover, Germany | Recruiting |
| UKSH Campus Lübeck | Lübeck, Germany | Recruiting |
| Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz | Mainz, Germany | Recruiting |
| Universitätsklinik Münster | Münster, Germany | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06440993